Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-981164 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.1 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.01 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.03 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.06 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.1 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 0.3 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 1 mg/kg solution subcutaneously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously |
| Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 1 mg/kg solution intravenously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously |
| Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 3 mg/kg solution intravenously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously |
| Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo | EXPERIMENTAL | Part 1 Single dose of BMS-981164 10.0 mg/kg solution intravenously OR Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously |
| Dose Escalation- BMS-981164 or Placebo (dose group 1) | EXPERIMENTAL | Part 2 BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 3 mg/kg, once, single dose OR Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 0 mg, once, single dose |
| Dose Escalation- BMS-981164 or Placebo (dose group 2) | EXPERIMENTAL | Part 2 BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0.1 mg/kg, once, single dose OR Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose |
| Dose Escalation- BMS-981164 or Placebo (dose group 3) | EXPERIMENTAL | Part 2 BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 0.1 mg/kg, once, single dose OR Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose |
| Dose Escalation- BMS-981164 or Placebo (dose group 4) | EXPERIMENTAL | Part 2 BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 3.0 mg/kg and \>1.0mg/kg, once, single dose OR Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose |
| Name | Type | Description |
|---|---|---|
| BMS-981164 | BIOLOGICAL | - |
| Placebo matching with BMS-981164 | BIOLOGICAL | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Part 1: Healthy subjects * Part 2: Adult subjects with: 1. Atopic dermatitis severity as assessed by Physician Global Assessment rating of 3 or higher (i.e., moderate or g...
BMS-981164 is an investigational monoclonal antibody being studied for use in healthy subjects and adults with atopic dermatitis. It is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 1 clinical development.
BMS-981164 targets interleukin-31 (IL-31), as indicated by its trial title. It is an anti-interleukin 31 monoclonal antibody designed to bind to this cytokine, which is involved in immune signaling.
BMS-981164 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY on the stock market. The company is conducting clinical trials to evaluate this investigational monoclonal antibody.
BMS-981164 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, with no active trials currently ongoing.
BMS-981164 has been studied in one completed Phase 1 clinical trial, identified as NCT01614756. This was a two-part, single-dose study conducted in the United Kingdom, enrolling 93 participants, including healthy subjects and adults with atopic dermatitis.
BMS-981164 is an anti-interleukin 31 (IL-31) monoclonal antibody. The clinical trial for this drug is titled 'A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody)', indicating that BMS-981164 is the IL-31 monoclonal antibody being tested.